Advisory Committee on Heritable Disorders in Newborns and Children, 18573 [2018-08853]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 82 / Friday, April 27, 2018 / Notices
highlighting further the
interrelationship between a clinical
protocol and an imaging charter.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on clinical trial
imaging endpoint process standards. It
does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations. This guidance is not subject
to Executive Order 12866.
II. The Paperwork Reduction Act of
1995
This guidance refers to previously
approved collections of information that
are subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR parts 312 and
314 have been approved under OMB
control numbers 0910–0014 and 0910–
0001, respectively.
III. Electronic Access
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/default.htm,
https://www.fda.gov/BiologicsBlood
Vaccines/GuidanceCompliance
RegulatoryInformation/default.htm, or
https://www.regulations.gov.
Dated: April 24, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–08903 Filed 4–26–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Committee on Heritable
Disorders in Newborns and Children
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of Meeting.
daltland on DSKBBV9HB2PROD with NOTICES
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Advisory
Committee on Heritable Disorders in
Newborns and Children (ACHDNC) will
hold a public meeting.
DATES: Wednesday, May 9, 2018, from
9:30 a.m. to 5:00 p.m. Eastern Time (ET)
SUMMARY:
VerDate Sep<11>2014
18:18 Apr 26, 2018
Jkt 244001
and Thursday, May 10, 2018, from 9:30
a.m. to 1:00 p.m. ET.
ADDRESSES: The public may attend this
meeting in person or via Webcast. While
this meeting will be open to the public,
advance registration is required. Please
register online at https://www.achdnc
meetings.org/ by 12:00 p.m. ET on May
7, 2018.
The address for the meeting is 5600
Fishers Lane, Rockville, MD 20857.
Non-U.S. citizens planning to attend in
person will need to provide additional
information to HRSA by Monday, April
30, 2018, 12 p.m. ET. To facilitate access
to the building, please contact Ann
Ferrero at the contact information listed
below. Individuals who plan to attend
and need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
notify Ms. Ferrero at least 10 days prior
to the meeting.
The meeting will also be accessible
via Webcast. Instructions on how to
access the meeting via Webcast will be
provided upon registration.
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
regarding the ACHDNC should contact
Ann Ferrero, Maternal and Child Health
Bureau (MCHB), HRSA, in one of three
ways: (1) Send a request to the following
address: Ann Ferrero, MCHB, HRSA
5600 Fishers Lane, Room 18N100C,
Rockville, MD 20857; (2) call 301–443–
3999; or (3) send an email to AFerrero@
hrsa.gov.
SUPPLEMENTARY INFORMATION:
Background: The ACHDNC provides
advice and recommendations to the
Secretary of HHS on the development of
newborn screening activities,
technologies, policies, guidelines, and
programs for effectively reducing
morbidity and mortality in newborns
and children having, or at risk for,
heritable disorders. In addition,
ACHDNC’s recommendations regarding
inclusion of additional conditions and
inherited disorders for screening are
included in the Recommended Uniform
Screening Panel (RUSP) following
adoption by the Secretary. Conditions
listed on the RUSP constitute part of the
comprehensive preventive health
guidelines supported by HRSA for
infants and children under section 2713
of the Public Health Service Act (42
U.S.C. 300gg–13). Under this provision,
non-grandfathered health plans and
health insurance issuers are required to
provide insurance coverage without
cost-sharing (a co-payment, coinsurance, or deductible) for screenings
included in the HRSA-supported
comprehensive guidelines for plan years
(i.e., policy years) beginning on or after
PO 00000
Frm 00073
Fmt 4703
Sfmt 9990
18573
the date that is one year from the
Secretary’s adoption of the condition for
screening.
Agenda: The meeting agenda will
include: (1) Presentations and
discussion on risk assessment in
newborn screening; (2) presentation of
educational tools for communicating
newborn screening results; (3)
presentations from states working
toward timeliness goals in newborn
screening; (4) an update on the status of
newborn screening pilot studies for
Guanidinoacetate Methyltransferase
(GAMT) deficiency; (5) updates from the
Laboratory Standards and Procedures
workgroup; (6) updates from the Followup and Treatment workgroup; (7)
updates from the Education and
Training workgroup; and (8) reviewing
the process for assessing the public
health impact of adding conditions to
the RUSP.
There are no votes scheduled for this
meeting. The final meeting agenda will
be available two (2) days prior to the
meeting on the Committee’s website at
https://www.hrsa.gov/advisorycommittees/heritable-disorders/
index.html. Please note that agenda
items and meeting times are subject to
change as priorities dictate.
Public Participation: Members of the
public will have the opportunity to
provide comments, which are part of the
official Committee record. To submit
written comments or request time for an
oral comment at the meeting, please
register online by 12:00 p.m. ET on May
3, 2018, at https://www.achdnc
meetings.org/. Oral comments will be
honored in the order they are requested
and may be limited as time allows.
Individuals associated with groups or
who plan to provide comments on
similar topics may be asked to combine
their comments and present them
through a single representative. No
audiovisual presentations are permitted.
Written comments should identify the
individual’s name, address, email,
telephone number, professional or
organization affiliation, background or
area of expertise (i.e., parent, family
member, researcher, clinician, public
health, etc.) and the topic/subject
matter.
Amy P. McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2018–08853 Filed 4–26–18; 8:45 am]
BILLING CODE 4165–15–P
E:\FR\FM\27APN1.SGM
27APN1
]]>Agencies
[Federal Register Volume 83, Number 82 (Friday, April 27, 2018)]
[Notices]
[Page 18573]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-08853]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Committee on Heritable Disorders in Newborns and
Children
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of Meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, this
notice announces that the Advisory Committee on Heritable Disorders in
Newborns and Children (ACHDNC) will hold a public meeting.
DATES: Wednesday, May 9, 2018, from 9:30 a.m. to 5:00 p.m. Eastern Time
(ET) and Thursday, May 10, 2018, from 9:30 a.m. to 1:00 p.m. ET.
ADDRESSES: The public may attend this meeting in person or via Webcast.
While this meeting will be open to the public, advance registration is
required. Please register online at https://www.achdncmeetings.org/ by
12:00 p.m. ET on May 7, 2018.
The address for the meeting is 5600 Fishers Lane, Rockville, MD
20857. Non-U.S. citizens planning to attend in person will need to
provide additional information to HRSA by Monday, April 30, 2018, 12
p.m. ET. To facilitate access to the building, please contact Ann
Ferrero at the contact information listed below. Individuals who plan
to attend and need special assistance, such as sign language
interpretation or other reasonable accommodations, should notify Ms.
Ferrero at least 10 days prior to the meeting.
The meeting will also be accessible via Webcast. Instructions on
how to access the meeting via Webcast will be provided upon
registration.
FOR FURTHER INFORMATION CONTACT: Anyone requesting information
regarding the ACHDNC should contact Ann Ferrero, Maternal and Child
Health Bureau (MCHB), HRSA, in one of three ways: (1) Send a request to
the following address: Ann Ferrero, MCHB, HRSA 5600 Fishers Lane, Room
18N100C, Rockville, MD 20857; (2) call 301-443-3999; or (3) send an
email to [email protected].
SUPPLEMENTARY INFORMATION:
Background: The ACHDNC provides advice and recommendations to the
Secretary of HHS on the development of newborn screening activities,
technologies, policies, guidelines, and programs for effectively
reducing morbidity and mortality in newborns and children having, or at
risk for, heritable disorders. In addition, ACHDNC's recommendations
regarding inclusion of additional conditions and inherited disorders
for screening are included in the Recommended Uniform Screening Panel
(RUSP) following adoption by the Secretary. Conditions listed on the
RUSP constitute part of the comprehensive preventive health guidelines
supported by HRSA for infants and children under section 2713 of the
Public Health Service Act (42 U.S.C. 300gg-13). Under this provision,
non-grandfathered health plans and health insurance issuers are
required to provide insurance coverage without cost-sharing (a co-
payment, co-insurance, or deductible) for screenings included in the
HRSA-supported comprehensive guidelines for plan years (i.e., policy
years) beginning on or after the date that is one year from the
Secretary's adoption of the condition for screening.
Agenda: The meeting agenda will include: (1) Presentations and
discussion on risk assessment in newborn screening; (2) presentation of
educational tools for communicating newborn screening results; (3)
presentations from states working toward timeliness goals in newborn
screening; (4) an update on the status of newborn screening pilot
studies for Guanidinoacetate Methyltransferase (GAMT) deficiency; (5)
updates from the Laboratory Standards and Procedures workgroup; (6)
updates from the Follow-up and Treatment workgroup; (7) updates from
the Education and Training workgroup; and (8) reviewing the process for
assessing the public health impact of adding conditions to the RUSP.
There are no votes scheduled for this meeting. The final meeting
agenda will be available two (2) days prior to the meeting on the
Committee's website at https://www.hrsa.gov/advisory-committees/heritable-disorders/. Please note that agenda items and
meeting times are subject to change as priorities dictate.
Public Participation: Members of the public will have the
opportunity to provide comments, which are part of the official
Committee record. To submit written comments or request time for an
oral comment at the meeting, please register online by 12:00 p.m. ET on
May 3, 2018, at https://www.achdncmeetings.org/. Oral comments will be
honored in the order they are requested and may be limited as time
allows. Individuals associated with groups or who plan to provide
comments on similar topics may be asked to combine their comments and
present them through a single representative. No audiovisual
presentations are permitted. Written comments should identify the
individual's name, address, email, telephone number, professional or
organization affiliation, background or area of expertise (i.e.,
parent, family member, researcher, clinician, public health, etc.) and
the topic/subject matter.
Amy P. McNulty,
Acting Director, Division of the Executive Secretariat.
[FR Doc. 2018-08853 Filed 4-26-18; 8:45 am]
BILLING CODE 4165-15-P
